NAD+ (nicotinamide adenine dinucleotide) is a coenzyme naturally present in every cell, essential to energy metabolism and DNA repair, and central to a large body of aging and longevity research. Supplemental NAD+ and its precursors are widely discussed in the biohacking community for cellular energy and recovery.
NAD+ is a coenzyme central to cellular energy metabolism and a required cofactor for sirtuins and PARP enzymes (DNA repair). NAD+ levels are well-documented to decline with age.
A systematic review of 10 RCTs (489 participants, across chronic fatigue syndrome, Parkinson's, Alzheimer's, diabetes-related conditions, and aging) reported benefits including reduced anxiety, decreased peak heart rate after stress testing, and improved muscle insulin sensitivity. de Mello Gindri et al., Am J Physiol Endocrinol Metab, 2024
Most NAD-boosting research studies precursors (NMN, nicotinamide riboside) rather than direct NAD+. A dose-ranging NMN trial (n=80, 60 days) found significantly increased blood NAD concentrations at all tested doses, with 600mg/day identified as the optimal dose. Yi et al., Geroscience, 2023
A randomized, placebo-controlled pilot comparing IV NAD+ directly against IV nicotinamide riboside (NR) found NAD+ IV (500mg) caused moderate-to-severe GI symptoms, increased heart rate, and chest pressure during infusion — meaningfully worse tolerability than NR IV, which had no significant adverse events. NAD+ IV infusions also took much longer to complete (~97 minutes average) than NR IV (~37 minutes) because of these reactions. (Preprint, not yet peer-reviewed — medRxiv, June 2024.)
This is a meaningfully different picture than the generic "well tolerated" framing common in this space — direct IV NAD+ specifically has a rougher tolerability profile than its precursor alternatives, per the one study that compared them head-to-head.
NMN precursor (oral, peer-reviewed): 300/600/900mg/day tested, 600mg/day identified as optimal. Direct NAD+ (IV, preprint): 500mg single dose tested. No subcutaneous NAD+ dosing trial was found.
Precursor forms (NMN, NR) look consistently well-tolerated across multiple studies — "no safety issues" found on monitoring in the 80-person NMN trial. Direct NAD+ IV has one real head-to-head comparison, and it came out worse-tolerated than the precursor alternative (see above).
Cellular energy production, DNA repair, and metabolic signaling; supplemental use is researched for fatigue, recovery, and aging-related cellular decline.
NAD+ is a naturally occurring molecule in the body, but supplemental/injectable forms sold for research use have not gone through the same safety review as an approved pharmaceutical.
NMN and NR are precursor molecules the body converts into NAD+; NAD+ itself is the final coenzyme, and each has a different absorption and delivery profile.
In terms of raw bioavailability, yes — injected NAD+ skips the multi-step conversion oral precursors need. But the honest caveat: there's no large controlled human trial comparing IV NAD+ against oral precursors head-to-head. What exists is strong mechanistic reasoning plus smaller trials and clinic-level observation, not a settled answer.
Real and well-documented — levels drop roughly 50% by midlife, tracking directly with mitochondrial dysfunction, inflammation, and slower cellular repair. What's less settled is how much restoring it actually changes how you feel or function.
Yes, reliably — oral NMN or NR consistently raises circulating NAD+ by roughly 130-150% in studies. Where it gets less impressive: short-term trials in older adults show only minimal improvement in cognition, vascular function, or muscle performance, despite that solid increase in the marker itself.
Looking for something specific, or placing a wholesale order? Send us a DM or email.